Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
May 15 2019 - 4:05PM
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced that its
abstract for BPX-601 has been accepted for poster presentation at
the 2019 American Society for Clinical Oncology (ASCO) Annual
Meeting. The meeting is being held May 31 – June 4, 2019 in
Chicago.
Details of the poster presentation are as follows:
Title: Ligand-Inducible, Prostate Stem Cell
Antigen (PSCA)-Directed GoCAR-T® Cells in Advanced Solid Tumors:
Preliminary Results with Cyclophosphamide (Cy) ± Fludarabine (Flu)
Lymphodepletion (LD)Poster Board: #180-Abstract
2536Presenter: Carlos R. Becerra,
M.D.Time/Location: Saturday, June 1, 8 to 11 a.m.
CDT, Hall A, Poster Session – Developmental Immunotherapy and Tumor
Immunobiology
About BPX-601
BPX-601, the company’s first GoCAR-T® product candidate,
incorporates iMC, Bellicum’s inducible co-activation domain. iMC
(inducible MyD88/CD40) is designed to provide a powerful boost to T
cell proliferation and persistence and enable the CAR-T to override
key immune inhibitory mechanisms, including PD-1 and TGF-beta.
BPX-601 is being evaluated as a treatment for solid tumors
expressing prostate stem cell antigen (PSCA), including pancreatic,
gastric, and prostate cancers.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving
to deliver cures through controllable cell therapies. The company’s
next-generation product candidates are differentiated by powerful
cell signaling technologies designed to produce more effective
CAR-T and allogeneic T cell therapies. Bellicum’s lead GoCAR-T®
candidate, BPX-601, is designed to be a more efficacious CAR-T cell
product capable of overriding key immune inhibitory mechanisms.
Bellicum’s rivo-cel product candidate is an allogeneic polyclonal T
cell therapy that has shown promising clinical trial results in
reducing leukemia relapse after a stem cell transplant. More
information can be found at www.bellicum.com.
Forward-Looking Statement
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Bellicum may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “designed,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research and development activities
relating to BPX-601 and our other pipeline candidates’
effectiveness, possible ranges of application and potential safety
and curative effects in the treatment of diseases, including as
compared to other treatment options and competitive therapies.
Various factors may cause differences between Bellicum’s
expectations and actual results as discussed in greater detail
under the heading “Risk Factors” in Bellicum’s filings with
the Securities and Exchange Commission, including without
limitation our quarterly report on Form 10-Q for the three months
ended March 31, 2019 and our annual report on Form 10-K the
year ended December 31, 2018. Any forward-looking statements
that Bellicum makes in this press release speak only as of the date
of this press release. Bellicum assumes no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Source: Bellicum Pharmaceuticals
Contacts: Investors:Robert H. Uhl Managing
Director Westwicke IR 858-356-5932 Robert.uhl@westwicke.com
Media: Jim Heins Senior Vice President Westwicke PR 203-682-8251
james.heins@icrinc.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024